Member Info for Titania

Sotrovimab FDA factsheet
https://www.fda.gov/media/149534/download

https://www.whitehouse.gov/live/

Pretty impressed by Polygon's trading capabilities - they seem to have bought every dip.

Good to hear about the testing chaos etc! Fauci calls Van Tam and Whitty once a week apparently!

“Right now, we’re back into a situation where there’s insufficient resources for those of us committed to keeping people well and healthy and not succumbing to this virus,” Wohl said. “This is a real frustration point and disappointment for many of us who’ve been in this now for almost two years.”

Read more at: https://www.heraldsun.com/news/coronavirus/article257193202.html#storylink=cpy

“Rise early. Work late. Strike oil.”

John D. Rockefeller

But officials in the White House Office of Management and Budget and Department of Health and Human Services have started putting together a longer-term funding request that is expected to ask Congress for tens of billions of dollars more, likely centered around covid-19 therapeutics and ramping up vaccine distribution, the people said.

https://www.washingtonpost.com/us-policy/2022/01/07/white-house-covid-aid/

https://www.indiatvnews.com/health/omicron-scare-study-finds-intense-meditation-may-boost-immunity-covid-coronavirus-2022-01-08-753349

So are Polar to phase 3 what Acacia were to phase 2?

https://mobile.twitter.com/lancelot_pinto/status/1389836814811222018?lang=ca

In an interview the BioNTech founders said they got the call on their trial on Sunday and they went out to the market Monday. So no time to leak. This will fit with what might have happened to us with phase 2.

So with Ndn71 here on the main results. While it would be great if the tweek or Ashfield were to be a sign that the company knows, they are more in line with RM who has always believed that they are "the one".

Now they might know something from Activ -2 phase 2 as its unclear whether this data is shared.

https://www.contractpharma.com/contents/view_breaking-news/2022-01-06/synairgen-partners-with-ashfield-engage-to-support-the-commercialization-of-sng001/

Seems to be some growing noise on Merck's antiviral molnupiravir could cause dangerous variants - it works by causing mutations. I know the board has been there before in November but was wondering if anyone has seen anything robust on this recently.

If its right, the UK anti-viral strategy is looking dodgy. One could cause variants and the other takes 6-8 months to manufacture.

"The gene expression levels that were altered in response to influenza infection varied significantly depending on the individual’s ancestry. “We found that individuals with a higher proportion of European ancestry showed an increase in type I interferon pathway activity during early influenza infection,” said Barreiro, speaking to GEN. Interestingly, the genetic ancestry effects are highly cell-type specific, however the results do not indicate genetic differences in disease susceptibility – genetics may have a role, but it is not the only factor."

https://www.biotechniques.com/immunology/genetic-ancestry-one-piece-of-the-immune-response-puzzle/

"In addition, there is growing evidence of the therapeutic benefits of inhaled interferon beta 1a and based on the study results this should be particularly the case for patients with weak or absent interferon activation."

https://indiaeducationdiary.in/ucl-rapid-immune-response-in-children-protects-them-from-covid-19/

https://www.whitehouse.gov/live/

https://www.fda.gov/media/149534/download

"Before Christmas, HHS said 55,000 doses of sotrovimab were distributed that week and another 300,000 are slated for distribution this month."

"Under Food and Drug Administration guidelines, the treatment is not available for those hospitalized due to COVID-19 or who require oxygen therapy."

https://thetexan.news/texas-running-low-on-monoclonal-antibody-therapy-after-federal-government-halted-distribution/

Session on: should more lateral flow tests be manufactured in the UK? Up shortly.

British manufacturers of lateral flow tests are battling with the government after their kits failed to be cleared for use in this country, despite being available in Europe.

The government invested millions of pounds to create a home-grown testing industry but only one British producer has managed to make a rapid test that meets UK requirements.

Despite the aims of Operation Moonshot to build up world-leading production in the UK, the majority of NHS home antigen tests are now two brands imported from China.

https://www.thetimes.co.uk/article/delays-in-approval-mean-uk-lateral-flow-kits-dont-pass-the-red-tape-test-kt57sxbzn

Also: The Cambridge and Yorkshire company Avacta had to suspend sales of its AffiDX antigen test in November because it had not yet passed the new CDTA checks despite being entered for it before a September deadline. It has yet to be given the go-ahead in Britain. It was the first UK-developed test to be CE certified for consumer self-testing last month but can only be sold abroad.